- Home
- MATH vs CRVO Comparison
MATH vs CRVO Comparison
Compare MATH & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- CRVO
- Stock Information
- Founded
- MATH 2015
- CRVO 2001
- Country
- MATH Hong Kong
- CRVO United States
- Employees
- MATH N/A
- CRVO N/A
- Industry
- MATH Finance/Investors Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- MATH Finance
- CRVO Health Care
- Exchange
- MATH Nasdaq
- CRVO Nasdaq
- Market Cap
- MATH 60.8M
- CRVO 67.4M
- IPO Year
- MATH N/A
- CRVO N/A
- Fundamental
- Price
- MATH $3.28
- CRVO $10.51
- Analyst Decision
- MATH
- CRVO Strong Buy
- Analyst Count
- MATH 0
- CRVO 6
- Target Price
- MATH N/A
- CRVO $20.80
- AVG Volume (30 Days)
- MATH 142.4K
- CRVO 119.1K
- Earning Date
- MATH 10-30-2025
- CRVO 08-08-2025
- Dividend Yield
- MATH N/A
- CRVO N/A
- EPS Growth
- MATH N/A
- CRVO N/A
- EPS
- MATH 0.41
- CRVO N/A
- Revenue
- MATH $44,567,257.00
- CRVO $7,776,968.00
- Revenue This Year
- MATH N/A
- CRVO N/A
- Revenue Next Year
- MATH N/A
- CRVO N/A
- P/E Ratio
- MATH $8.00
- CRVO N/A
- Revenue Growth
- MATH 165.86
- CRVO N/A
- 52 Week Low
- MATH $0.80
- CRVO $1.80
- 52 Week High
- MATH $4.17
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- MATH 56.90
- CRVO 63.06
- Support Level
- MATH $3.05
- CRVO $9.61
- Resistance Level
- MATH $3.35
- CRVO $10.89
- Average True Range (ATR)
- MATH 0.21
- CRVO 0.67
- MACD
- MATH 0.07
- CRVO 0.04
- Stochastic Oscillator
- MATH 89.23
- CRVO 70.28
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.